Jump Financial LLC Buys New Shares in COMPASS Pathways plc (NASDAQ:CMPS)

Jump Financial LLC purchased a new stake in shares of COMPASS Pathways plc (NASDAQ:CMPS) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 42,400 shares of the company’s stock, valued at approximately $371,000. Jump Financial LLC owned about 0.07% of COMPASS Pathways as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the stock. Conservest Capital Advisors Inc. bought a new stake in shares of COMPASS Pathways during the 4th quarter worth about $91,000. TAP Consulting LLC increased its stake in shares of COMPASS Pathways by 14.7% during the third quarter. TAP Consulting LLC now owns 12,845 shares of the company’s stock worth $95,000 after purchasing an additional 1,645 shares during the period. EWA LLC acquired a new stake in COMPASS Pathways during the 4th quarter worth approximately $107,000. Raymond James & Associates bought a new stake in COMPASS Pathways in the 3rd quarter valued at $205,000. Finally, Bank of New York Mellon Corp acquired a new position in COMPASS Pathways in the 3rd quarter valued at $597,000. 46.19% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other COMPASS Pathways news, Director George Jay Goldsmith sold 15,740 shares of the company’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $10.58, for a total value of $166,529.20. Following the completion of the transaction, the director now owns 4,079,107 shares in the company, valued at approximately $43,156,952.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Ekaterina Malievskaia sold 17,765 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $10.45, for a total value of $185,644.25. Following the transaction, the director now owns 4,092,573 shares of the company’s stock, valued at $42,767,387.85. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director George Jay Goldsmith sold 15,740 shares of COMPASS Pathways stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $10.58, for a total value of $166,529.20. Following the sale, the director now owns 4,079,107 shares of the company’s stock, valued at approximately $43,156,952.06. The disclosure for this sale can be found here. Insiders have sold a total of 118,507 shares of company stock valued at $1,089,094 in the last 90 days. 4.25% of the stock is currently owned by corporate insiders.

COMPASS Pathways Stock Performance

Shares of COMPASS Pathways stock opened at $7.48 on Friday. The business has a 50-day simple moving average of $8.65 and a 200 day simple moving average of $8.71. COMPASS Pathways plc has a one year low of $5.01 and a one year high of $12.75. The company has a debt-to-equity ratio of 0.12, a current ratio of 15.23 and a quick ratio of 15.23. The firm has a market capitalization of $511.18 million, a price-to-earnings ratio of -3.16 and a beta of 2.39.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Thursday, February 29th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.16). On average, research analysts anticipate that COMPASS Pathways plc will post -2.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Morgan Stanley started coverage on shares of COMPASS Pathways in a report on Monday, April 1st. They set an “overweight” rating and a $30.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 price objective on shares of COMPASS Pathways in a report on Monday, May 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of COMPASS Pathways in a report on Tuesday, April 30th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $47.40.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.